Vitiligo – Adults

Adults who have a diagnosis of non-segmental vitiligo may qualify for this clinical research trial and receive investigational medication (recombinant IL-2M) or placebo.

• Age: ≥ 18 years old
• Vitiligo for ≥ 3 months
• BSA ≥ 4% and facial BSA ≥ 0.5%
• All Fitzpatrick skin types
• No previous exposure to JAK inhibitors

Patients will be asked to visit the clinic about 17 times over approximately 104 weeks. There is no cost to participate, and participants will be reimbursed for their time and travel.

For further information on the study, please follow the link:

Study Details | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (Tranquillo 2) | ClinicalTrials.gov

Trial ID: NCT06072183

If you are interested in participating in a vitiligo clinical trial, please submit your details and our team will be in touch: expression of interest form